GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.

GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Novii™+ Wireless Patch Solution. The antepartum and intrapartum maternal and fetal monitor noninvasively measures and displays fetal heart rate, maternal heart rate and uterine activity, so care teams can have a real-time view of patient data. Through its belt-free and wireless design, Novii+ enables mobility and freedom for mother.

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. Cardiovascular disease is the leading cause of death globally - affecting millions of individuals and placing a significant burden on healthcare systems today. 1 Within the complex umbrella of cardiology care and cardiovascular disease, atrial fibrillation (AFib.

GE HealthCare Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information.

GE HealthCare to Announce Fourth Quarter and Full Year 2023 Results on February 6, 2024

GE HealthCare Technologies is potentially undervalued by up to 50%. The company reported strong financial results in Q3 2023, with 6% organic revenue growth and positive demand. GEHC's focus on AI applications, digital capabilities, and presence in China position it for future growth in the healthcare sector.

Why GE HealthCare May Be Up To 50% Undervalued

GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.

GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. GE HealthCare expects to leverage MIM Software's imaging analytics and digital workflow capabilit.

GE HealthCare announces agreement to acquire MIM Software

Management's plans to expand profit margins were boosted by its ongoing success at launching new products. The stock remains an excellent option for investors looking for healthcare exposure in their portfolio.

Why Shares in GE HealthCare Technologies Soared in December

DaVita

Hologic

Here are some dirt-cheap MedTech value stocks - DVA, GEHC, HOLX - which are expected to provide long-term gains.

3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2024

Medtronic

Investors looking to tap the budding prospects in the lucrative AI market in 2024 can count on Medtronic (MDT), GE HealthCare Technologies (GEHC) and Hologic (HOLX).

3 MedTech Stocks With Potential to Benefit From AI Boom in 2024

Aurora Innovation

Palo Alto Networks

It's rather difficult for retail investors to make money with short-term trades for several reasons. First of all, the Street frequently causes stocks to suddenly and unexpectedly rise or fall, ruining “momentum trades.

3 Long-Term Stocks You'll Regret Not Buying Soon: December Edition

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will attend the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th in San Francisco. Both GE HealthCare executives will participate in a Q&A session following Arduini's presentation at 2:15 pm ET/11:15 am PT. This live webcast can be accessed by visiting GE HealthCare's Investor R.

GE HealthCare Management to Present at 42nd Annual J.P. Morgan Healthcare Conference

After reaching an important support level, GE HealthCare Technologies (GEHC) could be a good stock pick from a technical perspective. GEHC surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

GE HealthCare Technologies (GEHC) Crossed Above the 200-Day Moving Average: What That Means for Investors

Intuitive Surgical

Schrodinger 

Artificial intelligence is being applied across the healthcare sector to improve delivery overall. AI stocks have the potential to impact stock sectors across the market positively, and healthcare is no different in that regard.

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

GE HealthCare Technologies has underperformed the market since July, down 16% while the S&P 500 has increased by 0.6%. The company's revenue has grown in its PDx, PCS, and Imaging segments, but net income has fallen due to higher expenses. Despite the lower profits, the company's stock is attractively priced and has significant upside potential, with estimates ranging from 52% to 102.5%.

GE HealthCare Technologies Remains Ridiculously Undervalued

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023 payable on February 15, 2024 to all shareholders of record as of January 16, 2024. About GE HealthCare GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hos.

GE HealthCare Announces Cash Dividend for Fourth Quarter of 2023

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and AirStrip, a vendor-agnostic clinical surveillance technology company and a member of the Nantworks group of AI driven companies, announced today a joint commercialization agreement. GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that.

Nantworks AirStrip® and GE HealthCare Announce Agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems

CHICAGO--(BUSINESS WIRE)--GE HealthCare is proud to announce the addition of True Enhance DL to its Effortless Recon DL portfolio.

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

CHICAGO--(BUSINESS WIRE)--Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX. The updated PTX algorithm expands Critical Care Suite's on-device triage capabilities by providing immediate notification of the presence or absence of pneumothorax, as well as an overlay display both on-device and in PACS to assist with PTX localization. X-.

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

U.S. equities fell to open the new trading week ahead of the release of the Fed's favorite measure of inflation, which could give hints as to where interest rates are heading. The S&P 500 dropped 0.2%, only its second losing session in the past nine.

S&P 500 Gains and Losses Today: GE HealthCare Technologies Downgraded

Crown Castle International

U.S. equities were mixed and little changed at midday Monday ahead of key inflation data due later in the week. The Dow and S&P 500 lost ground, while the Nasdaq was in the green.

Midday Movers: GE HealthCare Slumps, Crown Castle Advances

CHICAGO--(BUSINESS WIRE)--GE HealthCare announces new AI platform to support clinicians with breast cancer detection, improved workflow productivity - MyBreastAI Suite.

GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE HealthCare Technologies Inc.'s stock GEHC fell 2.8% in premarket trade Monday, after UBS downgraded the stock to sell from neutral and cut its price target to $66 from $86. Analysts led by Graham Doyle said a combination of slower order momentum, tough comparables and a lack of pricing tailwinds has left them below consensus on certain earnings metrics.

GE HealthCare's stock slides premarket after UBS downgrade to sell

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will highlight more than 40 innovations, including several key artificial intelligence (AI)-enabled technologies within the Imaging, Ultrasound, and digital space at the Radiological Society of North America's (RSNA) 2023 Annual Meeting taking place Nov. 26-30 in Chicago, IL. Each connected care solution is designed to better support clinicians, improve patient care, and increase health system efficiency at a time when healthcare system cha.

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received U.S. FDA 510(k) Clearance for the new version of Digital Expert Access with remote scanning, the first remote patient scan solution with 510(k) Clearance. Digital Expert Access enables the sharing of expertise, best practices, and in-the-moment advice, as well as real-time, remote console control. Now, with the new version of Digital Expert Access with remote scanning, this innovative solution has evolved to also enable remote.

GE HealthCare Announces New Version of Digital Expert Access, the First FDA 510(k)-Cleared Device to Enable Remote Patient Scanning, and Exclusive Distribution Agreement with IONIC Health

News for GE HealthCare Technologies Inc Stock (GEHC)